Study of Prevalence of Rifampicin resistance among cases of pulmonary Tuberculosis at tertiary care center

 

Anjali Surykant Deshmukh¹, Sanjiv Vithalrao Zangde^2*

 

Abstract              Background: The advent of multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid, as well as rifampicin-resistant tuberculosis (RR-TB), has posed a significant challenge to global TB control. Aims and Objectives: To Study Prevalence of Rifampicin resistance among cases of pulmonary Tuberculosis at tertiary care center. Methodology: The present study is an observational cross-sectional study of the patients with pulmonary tuberculosis attending Department of Pulmonary Medicine at a tertiary care centre during period of 1 January 2019 to 30 June 2020 by the permission of Institutional Ethical Committee Genexpert test / CBNAAT [ Xpert MTB/RIF Assay] Statistical analysis done buy of (version 20) for Windows package (SPSS Science, Chicago, IL, USA). Result: Majority of the study population were in the age group of 21- 30 years, followed by 31-40 years, the least recorded study subjects were in the age group of 51-60 years. Among all 200 cases GeneXpert assay/ CBNAAT was positive for MTB in 186 (93%) patients, among 186 MTB detected 168 (84%) were Rifampicin sensitive while 18 (9%) were Rifampicin Resistant and 14(7%) patients had Negative GeneXpert assay results. Conclusion: In our study the Prevalence of Rifampicin resistance found to be 7% hence GeneXpert assay found to be very useful for the detection of Refampicin resistance

Key words: Rifampicin resistance, GeneXpert assay, MTB.